ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the res...

Descripción completa

Detalles Bibliográficos
Autores principales: Griguolo, Gaia, Brasó-Maristany, Fara, González-Farré, Blanca, Pascual, Tomás, Chic, Núria, Saurí, Tamara, Kates, Ronald, Gluz, Oleg, Martínez, Débora, Paré, Laia, Tsvetkova, Vassilena, Pesantez, David, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Galván, Patricia, Barberá, Laura, Cuatrecasas, Miriam, Christgen, Mathias, Kreipe, Hans, Monge-Escartín, Inés, Villagrasa, Patricia, Soy, Dolors, Giarratano, Tommaso, Dieci, Maria Vittoria, Conte, Pierfranco, Harbeck, Nadia, Guarneri, Valentina, Prat, Aleix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409149/
https://www.ncbi.nlm.nih.gov/pubmed/32674482
http://dx.doi.org/10.3390/cancers12071902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409149/
https://www.ncbi.nlm.nih.gov/pubmed/32674482
http://dx.doi.org/10.3390/cancers12071902

Ejemplares similares